Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer

Gynecologic Oncology

Volumn 82, Issue 1, 2001, Pages 99-104

  Gotlieb, Walter H ^a   Goldberg, Iris ^a   Weisz, Boaz ^a   Davidson, Ben ^a   Novikov, Ilya ^a   Kopolovic, Juri ^a   Ben Baruch, Gilad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Immunohistochemistry; Ki 67; Ovarian cancer; Survival; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 0034936681     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6208     Document Type: Article

References (40)

1. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience
2. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience
3. Oncogene expression: Long-term compared with short-term survival in patients with advanced epithelial ovarian cancer
4. Clinical tumour markers in ovarian cancer
5. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol
6. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
7. p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry
8. Hormonal responses to large paracentesis: Are discordant results due to technologic differences?
9. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival
10. Determination of proliferation index with MIB-I in advanced ovarian cancer using quantitative image analysis
11. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure
12. Predictive value of proliferative cellular nuclear antigen (PCNA) and Ki-67 antigen in advanced stage serous papilliferous ovarian cancer
13. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
14. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
15. Structure of DNA topoisomerases
16. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints
17. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor
18. Expression of extracellular matrix proteins in cervical squamous cell carcinoma - A clinicopathological study
19. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction
20. The use of avidin-biotin interaction in immunoenzymatic techniques
21. Immunohistochemical determination of tumour growth fraction in human ovarian carcinoma
22. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers
23. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis
24. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer
25. DNA topoisomerase poisons as antitumor drugs
26. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines
27. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line
28. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells
29. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer
30. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors
31. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer
32. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein
33. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas
34. Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer
35. Cytoreductive surgery for ovarian cancer
36. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer. Impact on survival
37. Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs
38. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells
39. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma